Phase 2 Trial Fails to Meet Objectives
Drug development efforts at Tvardi Therapeutics have faced a major hurdle as the company’s experimental therapy TTI-101 failed to meet key goals in its Phase 2 IPF trial. Tvardi Therapeutics has released preliminary data from its phase 2 REVERT trial evaluating TTI-101, a STAT3 inhibitor developed to treat idiopathic pulmonary fibrosis (IPF). The Houston-based biotechnology company, which recently joined the Nasdaq through a reverse merger with Cara Therapeutics, said the study did not meet its objectives.
Trial Design and Execution
The trial tested two daily doses of TTI-101, 400 mg and 800 mg, against a placebo in 88 patients. Participants were randomly assigned to one of the treatment groups, with more than half also receiving nintedanib (Ofev), an approved anti-fibrotic therapy. The study was designed to assess safety, drug exposure, and potential effects on lung function over 12 weeks.
Disappointing Results and Side Effects
According to Tvardi, the discontinuation rate was higher among patients receiving TTI-101 compared with those given a placebo. The company attributed most treatment withdrawals to gastrointestinal side effects, noting that such events occurred more often in patients who took both TTI-101 and nintedanib.
When assessing lung function, the company observed no meaningful differences between patients on the study drug and those on placebo. Measures of Forced Vital Capacity (FVC) showed wide variation among participants, and improvements were recorded in similar proportions across all study groups. Tvardi said the smaller-than-expected decline in lung function among placebo-treated patients made it more difficult to draw clear conclusions about the treatment’s performance.
Company Commentary
“In the aggregate, we did not observe a benefit of TTI-101 treatment in this IPF study. The limited data set, high variability within treatment arms, and unexpected performance of the placebo arm make it difficult to provide more definitive conclusions at this time,” said Imran Alibhai, Ph.D., Chief Executive Officer of Tvardi. He added that the company is conducting further analyses to better understand the findings and determine next steps.
Future Pipeline and Next Steps
While TTI-101 fell short in IPF, Tvardi continues to develop the compound in other areas and is also advancing a next-generation STAT3 inhibitor, TTI-109. The newer molecule is designed to improve how the drug targets STAT3 and to potentially reduce tolerability issues observed with TTI-101. Alibhai said the company remains on track to share topline results from ongoing studies of TTI-109 and TTI-101 in liver cancer during the first half of 2026.
Financial Impact
As of June 30, 2025, Tvardi reported holding $41 million in cash, cash equivalents, and short-term investments, which it expects will support operations into the fourth quarter of 2026. Following the trial announcement, the company’s stock fell 85% to $6.25 in premarket trading.
In light of the REVERT trial’s disappointing outcome, Tvardi is now under pressure to clarify its strategic path forward. The company faces key questions about whether TTI-101 can be reformulated or dosed differently to mitigate gastrointestinal toxicity, especially when combined with nintedanib.
Should further analyses show biomarker subsets or patient populations who did benefit, Tvardi might pursue a targeted follow-on study. In parallel, the firm will need to revisit its risk-reward balance and the viability of TTI-101 as a contender in fibrosis.
Still, the company has some grounds for cautious optimism. Tvardi is actively advancing TTI-109, a next-generation STAT3 inhibitor, with the goal of improving both efficacy and tolerability. Meanwhile, its pipeline in liver cancer (the REVERT liver trial) continues to progress, offering a potential alternative path to value. If TTI-109 exhibits a more favorable safety profile, it may supplant TTI-101 in fibrotic indications and reenergize the company’s strategy.
Despite the recent setback, Tvardi remains committed to advancing its scientific vision in fibrosis and oncology. The company believes that understanding the mechanism of action behind its lead Drug, TTI-101, The company emphasized that the drug’s mechanism of action—targeting the STAT3 signaling pathway—remains a scientifically validated approach in fibrotic and oncologic diseases. Tvardi believes that further investigation into how the drug interacts with other standard-of-care treatments could uncover new opportunities for combination strategies.
